To Evaluate The Addon Effect Of Ghrita Guggul Sikthasya Dhumpan With Vyoshadi Vati In Allergic Rhinitis.

A Standard Controlled Clinical Trial To Evaluate The Addon Effect Of Ghrita Guggul Sikthasya Dhumpan With Vyoshadi Vati In Allergic Rhinitis. - RIGIDITY

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/04/032744

Enrollment

Registered

2021-04-12

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J309- Allergic rhinitis, unspecified

Interventions

Intervention1: Ghrita Guggul Sikthasya Dhumpan With Vyoshadi Vati: Group A 30 Patients will be treated with Vyoshadi Vati 250mg, 2 tablets vyanodane (after lunch, after dinner) for 21days with Ghrita

Eligibility

Inclusion criteria

Inclusion criteria: Patients from age group of 18 to 50 years irrespective of gender, religion, occupation having signs and symptoms of Allergic rhinitis - 1. Recurrent Sneezing 2. Watery Rhinorrhoea 3. Nasal Obstruction

Exclusion criteria

Exclusion criteria: 1. Known cases of chronic non-specific infective rhinitis like hypertrophic rhinitis, rhinitis sicca, rhinitis caseosa, atrophic rhinitis, malignant granuloma 2. Patients with Tumors, malignancy of any kind. 3. Pregnant women. 4. Patients having sign and symptoms of Covid-19

Design outcomes

Primary

Measure	Time frame
To Compare Addon Effect Of Ghrita Guggul Sikthasya Dhumpan To Vyoshadi Vati In Allergic Rhinitis.Timepoint: 21 Days with follow up on 8th, 15th, 22nd day and 1 month after completion of the treatment	—

Secondary

Measure	Time frame
To observe adverse effect of the drug, if anyTimepoint: 21 Days with follow up on 8th, 15th, 22nd day and 1 month after completion of the treatment	—

Countries

India

Contacts

Public ContactDr Chandana Virkar

PDEAs College of Ayurveda And Research Centre Akurdi Pune

drvirkarchandana@gmail.com9822199107

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026